Tarlatamab Administration and Postinfusion Monitoring
Panelists discuss how tarlatamab is administered via intravenous infusion with gradual dosing increases, emphasizing the importance of immediate postinfusion monitoring for acute reactions such as cytokine release syndrome, followed by ongoing follow-up to detect delayed adverse effects and manage potential immune-related toxicities.
Summary for Physicians:
Tarlatamab Administration:
- Route: Intravenous (IV) infusion
- Initial dosing: Start with lower doses to monitor for adverse effects, gradually increasing as tolerated.
- Infusion schedule: Typically given every 3 weeks during the initial treatment phase.
Monitoring Protocol Post Infusion:
- Immediate monitoring:
- Patients are observed for 1 to 2 hours post infusion to monitor for acute reactions such as cytokine release syndrome (CRS).
- Monitoring includes vital signs, oxygen saturation, and symptoms of infusion-related reactions.
- Ongoing monitoring:
- Regular follow-up visits (usually 24-48 hours post infusion) to assess for delayed adverse effects.
- Patients are educated on self-monitoring for symptoms such as fever, chills, or shortness of breath.
- Continuous assessment for immune-related toxicities.
Challenges:
Ensuring timely detection of CRS or other adverse events and having adequate support for emergency interventions.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
